Recently Added |View More
Phase 1 Clinical Trial Offers FDA Fast-Tracked Drug for Relapsed/Refractory AML and MDS
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center offers a promising treatment option for patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Clinical CAR T-cell Trial for Multiple Myeloma Suggests Possible “Cure”
For the first time, patients on a new CAR T-cell therapy for multiple myeloma are experiencing remission long enough to be cautious deemed cured of their disease.
Cellular Therapies Leading to New Treatment Options for Lymphoma Patients
A new CAR T-cell consortium, Matthew Cortese, MD, MPH, a hematologic oncologist at Roswell Park Comprehensive Cancer Center, shares that certain types of hard-to-treat lymphomas may be more receptive to immunotherapies than previously thought.
A meta-analysis led by a researcher at Roswell Park Comprehensive Cancer Center has identified key factors that could improve outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs) before or after a solid-organ transplant.
Experts from Roswell Park Comprehensive Cancer Center will give remarks on racial and ethnic disparities in outcomes among people with metastatic breast cancer; risk patterns for second cancers associated with human papillomavirus (HPV); ...
Roswell Park presentations include findings from KOMET-001 in AML, new insights on risk of organ rejection after ICI.
Working at Roswell Park will afford you incredible opportunities to work alongside some of the nation’s foremost clinicians and researchers to broaden your career experiences and be part of a team that eases the burden of cancer.
Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025
Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30.
Can Vitamin A Supplementation Reduce the Incidence of Chronic GVHD After Allogeneic Transplant?
Research has shown that vitamin A, which helps regulate a variety of immune responses, may have the potential to reduce the incidence of chronic GVHD or limit its severity.
This site is intended for healthcare professionals
Click your preferred app store below to download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.